Tianjing Biopharma has entered a strategic partnership with Sanofi to collaborate on the development and commercialization of its innovative CD73 antibody, Uliledlimab, in Greater China, aiming to enhance cancer treatment options.

Information on the Target

Tianjing Biopharma, referred to as "Tianjing," is a biotechnology company based in Hangzhou, China, with a focus on the development and commercialization of innovative biopharmaceuticals for autoimmune diseases and tumors. The company is backed by Via Biotech and has recently announced a strategic partnership with Sanofi for the development, production, and commercialization of its proprietary global innovative CD73 antibody, Uliledlimab, in Greater China. This collaboration aims to leverage Tianjing's cutting-edge research and manufacturing capabilities alongside Sanofi's established commercialization network, ultimately working to provide breakthrough treatment options for cancer patients and fulfill unaddressed clinical needs.

Uliledlimab is distinguished by its unique properties as a CD73 antibody, which modulates the tumor microenvironment and enhances the body's immune response against cancer cells. Currently, the antibody is undergoing pivotal studies in China in combination with Toripalimab for the treatment of metastatic non-small cell lung cancer (NSCLC). Data announced at the 2023 American Society of Clinical Oncology (ASCO) meeting demonstrated promising safety profiles and efficacy when Uliledlimab is used in conjunction with Toripalimab for patients with high CD73 expression.

Industry Overview in China

The biopharmaceutical industry in China has witnessed explosive growth in recent years, driven by rising investments in innovative drug development, increasing healthcare expenditures, and government initiatives aimed at nurturing a robust health economy. In particular, the oncology sector has seen a surge